In a cisgender woman treated for hypoactive sexual desire or mild androgen deficiency, does transdermal testosterone cream produce a higher conversion to dihydrotestosterone than intramuscular testosterone injections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

DHT Conversion: Transdermal vs. Intramuscular Testosterone

Yes, transdermal testosterone cream produces substantially higher conversion to dihydrotestosterone (DHT) compared to intramuscular injections—specifically, transdermal preparations elevate serum DHT 5.46-fold versus only 2.20-fold with intramuscular testosterone. 1

Evidence for Differential DHT Conversion

  • Transdermal testosterone (gel or cream) increases serum DHT by 5.46-fold (95% CI: 4.51 to 6.60), representing a 2.5-times greater elevation than intramuscular preparations 1

  • Intramuscular testosterone injections increase serum DHT by only 2.20-fold (95% CI: 1.74 to 2.77), a significantly lower magnitude of conversion 1

  • This difference in DHT elevation occurs despite both routes achieving similar increases in serum testosterone levels, indicating that the route of administration fundamentally alters the metabolic conversion pathway 1

Clinical Implications for Women with Hypoactive Sexual Desire

Formulation Selection

  • For cisgender women being treated for hypoactive sexual desire disorder or mild androgen deficiency, the higher DHT conversion with transdermal preparations may actually be therapeutically relevant, as DHT contributes to androgenic effects on sexual function 2, 3, 4

  • Transdermal testosterone cream (typically 1% formulation applied 5g twice weekly) has demonstrated efficacy in treating hypoactive sexual desire disorder in women, with improvements in libido and sexual function within 3 weeks 2

  • Intramuscular testosterone cypionate (100 mg monthly for 3 months) has also shown effectiveness for hypoactive sexual desire in both pre- and postmenopausal women, though with lower DHT conversion 3

Monitoring Considerations

  • When using transdermal testosterone in women, monitor free and total testosterone, complete blood count, lipid profiles, and liver function every 3 months due to the higher DHT conversion and potential for androgenic side effects 2

  • Common side effects with transdermal preparations include mild facial acne, which typically resolves within 2 months after treatment completion 2

  • The higher DHT elevation with transdermal preparations may theoretically increase cardiovascular risk, though this has not been definitively established in women 1

Cardiovascular Safety Profile by Route

  • Oral testosterone carries significant cardiovascular risk (RR = 2.20,95% CI: 1.45 to 3.55) and should be avoided 1

  • Intramuscular testosterone shows no significant cardiovascular risk (RR = 0.66,95% CI: 0.28 to 1.56) in meta-analysis of randomized controlled trials 1

  • Transdermal testosterone shows no significant cardiovascular risk (RR = 1.27,95% CI: 0.62 to 2.62), though the point estimate suggests potential for increased risk that warrants further research 1

  • The differential DHT elevation may underlie varying cardiovascular risk profiles, as elevated serum DHT has been associated with cardiovascular risk in observational studies 1

Treatment Algorithm for Women

For postmenopausal women with hypoactive sexual desire disorder:

  • Start with transdermal testosterone cream 1% (5g twice weekly) as first-line therapy, given demonstrated efficacy and patient preference for topical application 2, 4

  • Monitor testosterone levels (targeting physiologic female range), complete blood count, lipid profile, and liver function at baseline and every 3 months 2

  • Expect clinical response within 3 weeks; continue for at least 3-6 months to assess full therapeutic benefit 2, 3

  • If androgenic side effects (acne, hirsutism) become problematic with transdermal therapy, consider switching to intramuscular testosterone cypionate 100 mg monthly, which produces lower DHT conversion 1, 3

For premenopausal women:

  • Limited data support testosterone use in premenopausal women; consider only after thorough evaluation and discussion of off-label use and limited long-term safety data 4, 5

  • If treatment is pursued, use the same monitoring protocol as for postmenopausal women 2

Critical Caveats

  • No FDA-approved testosterone formulation exists for women in the United States due to lack of long-term safety data; all use is off-label 5

  • Current data do not support testosterone treatment for bone health, brain health, energy, or cognition in women—the indication is specifically for hypoactive sexual desire disorder 5

  • The higher DHT conversion with transdermal preparations is a pharmacologic fact, but whether this translates to superior or inferior clinical outcomes in women remains uncertain 1

  • Two clinical guidelines now provide expert guidance on testosterone treatment and monitoring in women for HSDD, which should be consulted before initiating therapy 5

References

Related Questions

What is the role of testosterone replacement therapy in women, particularly for hypoactive sexual desire disorder (HSDD)?
What are the recommendations and dosing (posology) for prescribing testosterone for Hypoactive Sexual Desire Disorder (HSDD) in women?
What hormone deficiency is directly associated with decreased libido, arousal, orgasm, and genital sensation in aging women?
What is the recommended starting dose and administration route for testosterone therapy in an adult woman with hypoactive sexual desire disorder, menopausal symptoms, or documented hypogonadism?
What is the recommended dosing for Androgel (testosterone) 1% in a postmenopausal female with Hypoactive Sexual Desire Disorder (HSDD)?
What is the recommended starting dose of testosterone cypionate for women?
What is the appropriate metoclopramide dose for a patient with end‑stage renal disease (CKD stage 5, creatinine clearance < 15 mL/min or on dialysis)?
How do I safely perform low‑fluence Q‑switched Nd:YAG facial laser toning in a 20‑50‑year‑old adult with mild melasma or diffuse hyperpigmentation, including pre‑treatment assessment, laser parameters, treatment schedule, and post‑procedure care?
What is the recommended low‑fluence Q‑switched Nd:YAG laser‑toning protocol for an adult (Fitzpatrick I‑IV) with melasma or diffuse facial hyperpigmentation, including contraindications and alternative treatments?
What are the optimal treatment options for a non‑productive cough in a bedridden post‑stroke patient?
What is eDKA (euglycemic diabetic ketoacidosis), what are its common precipitants, and how should it be diagnosed and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question